Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 201–300 of 2,517
Mirzayans, R., Andrais, B., Scott, A., & Murray, D. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/170325 · Cited by 257
“The insert vertical bars above the DNA-binding domain illustrate the distribution and the prevalence of point mutations found in p53 in human cancers [19, 20].”
BackgroundTan, M., Wang, Y., Guan, K., & Sun, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.109 · Cited by 252
Polyubiquitination by HECT E3s and the Determinants of Chain Type Specificity
Kim, H. C., & Huibregtse, J. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00240-09 · Cited by 252
“This was possible for Rsp5 substrates because of the small and welldefined modules that are the basis for enzyme substrate recognition (WW domain-PY motifs), but it was not possible for E6AP, which recognizes the DNA binding domain of p53 (42), which has several lysine residues that are critical for folding or functio…”
BackgroundCooperative Binding of Tetrameric p53 to DNA
Weinberg, R. L., Veprintsev, D. B., & Fersht, A. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.071 · Cited by 250
Wang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. Y.-H. P., & Zhu, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.001 · Cited by 250
“Cre-mediated recombination of this p53flox allele results in an in-frame deletion of exons 5 and 6 (Figure 1A), which encode a significant portion of the p53 DNA binding domain (Cho et al., 1994; Kitayner et al., 2006).”
Backgroundp53 Protein Exhibits 3′-to-5′ Exonuclease Activity
Mummenbrauer, T., Janus, F., Müller, B., Wiesmüller, L., Deppert, W., & Grosse, F. (1996) · Cell · doi:10.1016/s0092-8674(00)81309-4 · Cited by 249
TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors
Tabori, U., Shlien, A., Baskin, B., Levitt, S., Ray, P., Alon, N., Hawkins, C., Bouffet, E., Pienkowska, M., Lafay-Cousin, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8169 · Cited by 247
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Chen, S., Wu, J.-L., Liang, Y., Tang, Y.-G., Song, H.-X., Wu, L.-L., Xing, Y.-F., Yan, N., Li, Y.-T., Wang, Z.-Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.013 · Cited by 241
A p53-independent Pathway for Activation of WAF1/CIP1 Expression Following Oxidative Stress
Russo, T., Zambrano, N., Esposito, F., Ammendola, R., Cimino, F., Fiscella, M., Jackman, J., O'Connor, P. M., Anderson, C. W., & Appella, E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29386 · Cited by 246
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability
Nikolova, P. V., Henckel, J., Lane, D. P., & Fersht, A. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14675 · Cited by 240
Attardi, L. D., Lowe, S. W., Brugarolas, J., & Jacks, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00739.x · Cited by 238
Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239
Yates, C. M., & Sternberg, M. J. E. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.07.012 · Cited by 238
Cellular Senescence: Molecular Mechanisms, In Vivo Significance, and Redox Considerations
Muller, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2104 · Cited by 238
Gualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 237
Méplan, C., Richard, M.-J., & Hainaut, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203907 · Cited by 234
“Zinc binding by p53 was initially identi®ed on the basis of biochemical evidence and was con®rmed when the partial crystal structure of the protein was published (Cho et al., 1994; Pavletich et al., 1993).”
BackgroundResultInfluentialLee, H., Trainer, A. H., Friedman, L. S., Thistlethwaite, F. C., Evans, M. J., Ponder, B. A. J., & Venkitaraman, A. R. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80182-3 · Cited by 234
Pabo, C. O., & Nekludova, L. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3918 · Cited by 232
p53 alterations in human cancer: more questions than answers
Soussi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210280 · Cited by 232
“Two classes of mutations have been distinguished on the basis of various in vitro assays and the three-dimensional structure of the protein (Cho et al., 1994): class I mutations, exemplified by mutants at codon 248 (7.6% in the p53 database, http:// p53.free.fr/), affect amino acids directly…”
BackgroundInfluentialDiversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs
Kitayner, M., Rozenberg, H., Rohs, R., Suad, O., Rabinovich, D., Honig, B., & Shakked, Z. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1800 · Cited by 229
Westra, W. H., Taube, J. M., Poeta, M. L., Begum, S., Sidransky, D., & Koch, W. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1402 · Cited by 231
Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 228
The N-terminal Domain of p53 is Natively Unfolded
Dawson, R., Müller, L., Dehner, A., Klein, C., Kessler, H., & Buchner, J. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.008 · Cited by 229
Comparison of predicted and actual consequences of missense mutations
Miosge, L. A., Field, M. A., Sontani, Y., Cho, V., Johnson, S., Palkova, A., Balakishnan, B., Liang, R., Zhang, Y., Lyon, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511585112 · Cited by 222
“Interestingly, FP mutations were concentrated outside the core DNA-binding domain residues 102–292 (41) (Fig.”
BackgroundNordsmark, M., Alsner, J., Keller, J., Nielsen, O. S., Jensen, O. M., Horsman, M. R., & Overgaard, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1728 · Cited by 226
Cadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 225
Refined solution structure of the oligomerization domain of the tumour suppressor p53
Clore, G. M., Ernst, J., Clubb, R., Omichinski, J. G., Kennedy, W. M. P., Sakaguchi, K., Appella, E., & Gronenborn, A. M. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-321 · Cited by 222
p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study
Ahrendt, S. A., Hu, Y., Buta, M., McDermott, M. P., Benoit, N., Yang, S. C., Wu, L., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.961 · Cited by 222
Clinical implications of p53 mutations
Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050270 · Cited by 225
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223
Identification and characterization of a p53 homologue in Drosophila melanogaster
Jin, S., Martinek, S., Joo, W. S., Wortman, J. R., Mirkovic, N., Sali, A., Yandell, M. D., Pavletich, N. P., Young, M. W., & Levine, A. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7301 · Cited by 221
Self-citationHot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
Ng, K. W., Khoo, S. P. K., Heng, B. C., Setyawati, M. I., Tan, E. C., Zhao, X., Xiong, S., Fang, W., Leong, D. T., & Loo, J. S. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.036 · Cited by 220
“p53 is endogenously expressed but is quickly degraded upon MDM2 binding [23].”
BackgroundA Novel Cofactor for p300 that Regulates the p53 Response
Shikama, N., Lee, C.-W., France, S., Delavaine, L., Lyon, J., Krstic-Demonacos, M., & La Thangue, N. B. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80338-x · Cited by 218
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure
Joo, W. S., Jeffrey, P. D., Cantor, S. B., Finnin, M. S., Livingston, D. M., & Pavletich, N. P. (2002) · Genes & Development · doi:10.1101/gad.959202 · Cited by 220
“The L3 loop is one of the two key structural elements that make up the DNA-binding surface of p53, containing an arginine residue (Arg 248) that binds in the minor groove of the DNA (Cho et al. 1994).”
BackgroundMethodInfluentialSelf-citationiCn3D, a web-based 3D viewer for sharing 1D/2D/3D representations of biomolecular structures
Wang, J., Youkharibache, P., Zhang, D., Lanczycki, C. J., Geer, R. C., Madej, T., Phan, L., Ward, M., Lu, S., Marchler, G. H., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz502 · Cited by 216
p300 and CBP: Partners for life and death
Giordano, A., & Avantaggiati, M. L. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199911)181:2<218::aid-jcp4>3.0.co;2-5 · Cited by 291
Interaction of p53 with the Human Rad51 Protein
Buchhop, S., Gibson, M. K., Wang, X. W., Wagner, P., Sturzbecher, H.-W., & Harris, C. C. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.19.3868 · Cited by 215
Shen, J., Sheng, X., Chang, Z., Wu, Q., Wang, S., Xuan, Z., Li, D., Wu, Y., Shang, Y., Kong, X., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.042 · Cited by 213
“Coordinates of the p53-DNA complex were extracted from the Protein Data Bank (PDB 1TSR) (Cho et al., 1994) and visualized on PyMOL (DeLano Scientific).”
InfluentialArold, S., Franken, P., Strub, M.-P., Hoh, F., Benichou, S., Benarous, R., & Dumas, C. (1997) · Structure · doi:10.1016/s0969-2126(97)00286-4 · Cited by 209
“Although rarely observed, a similar packing constraint was described for the p53 tumor suppressor–DNA complex [58], where both one free and two DNA-liganded p53 molecules were present in the asymmetric unit.”
BackgroundOverexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma?
Moon, W. S., Rhyu, K. H., Kang, M. J., Lee, D. G., Yu, H. C., Yeum, J. H., Koh, G. Y., & Tarnawski, A. S. (2003) · Modern Pathology · doi:10.1097/01.mp.0000071841.17900.69 · Cited by 210
Tessier-Cloutier, B., Kortekaas, K. E., Thompson, E., Pors, J., Chen, J., Ho, J., Prentice, L. M., McConechy, M. K., Chow, C., Proctor, L., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0524-1 · Cited by 208
Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look
Soussi, T., & May, P. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0425 · Cited by 208
“This hypothesis has been confirmed by crystallographic data (Cho et al., 1994).”
BackgroundInfluentialLenz, H., Hayashi, K., Salonga, D. S., Danenberg, K. D., Danenberg, P. V., Metzger, R., Banerjee, D., Bertino, J. R., Groshen, S. G., Leichman, L. P., et al. (1998) · PubMed · Cited by 206
Comparative Binding of p53 to its Promoter and DNA Recognition Elements
Weinberg, R. L., Veprintsev, D. B., Bycroft, M., & Fersht, A. R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.03.014 · Cited by 205
Protein interactions and disease: computational approaches to uncover the etiology of diseases
Kann, M. G. (2007) · Briefings in Bioinformatics · doi:10.1093/bib/bbm031 · Cited by 201
“Structural analysis of mutations in p53 could facilitate the dissection of their functional role, in particular their effect on DNA-binding that seems to be key in human cancers [71, 72].”
Méplan, C., Mann, K., & Hainaut, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31663 · Cited by 203
Li, X., & Coffino, P. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4509-4516.1996 · Cited by 201
“A deletion of amino acids 1 to 160 destroys the wild-type conformation of p53 and should therefore limit 16E6 binding (4).”
Backgroundp53 Signaling and Cell Cycle Checkpoints
Stewart, Z. A., & Pietenpol, J. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000199t · Cited by 202
TP53: a key gene in human cancer
Guimaraes, D. P., & Hainaut, P. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01356-6 · Cited by 203
Velu, C. S., Niture, S. K., Doneanu, C. E., Pattabiraman, N., & Srivenugopal, K. S. (2007) · Biochemistry · doi:10.1021/bi700425y · Cited by 201
“The third one (C) makes contact with the B monomer, but, not with DNA (36).”
BackgroundMethodInfluentialNew approaches to understanding p53 gene tumor mutation spectra
Hollstein, M., Hergenhahn, M., Yang, Q., Bartsch, H., Wang, Z.-Q., & Hainaut, P. (1999) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00162-1 · Cited by 198
A Molecular Genetic Model of Astrocytoma Histopathology
Louis, D. N. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb01062.x · Cited by 199
Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001) · PubMed · Cited by 234
Inga, A., Storici, F., Darden, T. A., & Resnick, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8612-8625.2002 · Cited by 199
“, positions 3 and 4, as predicted by the crystal structure (16).”
BackgroundInfluentialGaal, T., Ross, W., Blatter, E. E., Tang, H., Jia, X., Krishnan, V. V., Assa-Munt, N., Ebright, R. H., & Gourse, R. L. (1996) · Genes & Development · doi:10.1101/gad.10.1.16 · Cited by 199
“loop interacts wi th the major groove in the p53-DNA complex (Cho et al. 1994).”
BackgroundWalker, D. R., Bond, J. P., Tarone, R. E., Harris, C. C., Makalowski, W., Boguski, M. S., & Greenblatt, M. S. (1999) · Oncogene · doi:10.1038/sj.onc.1202298 · Cited by 198
Fibrillar Aggregates of the Tumor Suppressor p53 Core Domain
Ishimaru, D., Andrade, L. R., Teixeira, L. S. P., Quesado, P. A., Maiolino, L. M., Lopez, P. M., Cordeiro, Y., Costa, L. T., Heckl, W. M., Weissmüller, G., et al. (2003) · Biochemistry · doi:10.1021/bi034218k · Cited by 196
Uversky, V. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111874 · Cited by 192
“Peculiarities of the structural perturbations induced in the ordered DBD by interaction with different partners (DNA [133], 53BP1 [134], 53BP2 [135], and the large-T antigen (LTag) from simian virus 40 [136]) were analyzed in the dedicated study, where it was pointed out that “multiple partners of p53 are accommodated…”
Background(2000) · PubMed
20 years studying p53 functions in genetically engineered mice
Donehower, L. A., & Lozano, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2731 · Cited by 168
“The p53-R172H mutation (corresponding to amino acid 175 in human p53) disrupts the structure of the DNA-binding domain and is one of the most aggressive mutants that has been examined in cell cultur”
Backgroundp53 Isoforms: Key Regulators of the Cell Fate Decision
Joruiz, S. M., & Bourdon, J.-C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026039 · Cited by 190
“2B) (Pavletich et al. 1993; Cho et al. 1994; Xue et al. 2009).”
Cabelguenne, A., Blons, H., de Waziers, I., Carnot, F., Houllier, A.-M., Soussi, T., Brasnu, D., Beaune, P., Laccourreye, O., & Laurent-Puig, P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1465 · Cited by 191
The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy
Bristow, R. G., Benchimol, S., & Hill, R. P. (1996) · Radiotherapy and Oncology · doi:10.1016/0167-8140(96)01806-3 · Cited by 192
Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73
Marin, M. C., Jost, C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., & Kaelin, W. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6316 · Cited by 193
“Furthermore, all of the residues that contact DNA in the p53-DNA crystal structure are conserved in p73 (7).”
BackgroundNEW EMBO MEMBERS' REVIEW: Hsp70 interactions with the p53 tumour suppressor protein
Zylicz, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4634 · Cited by 192
Long Non-Coding RNAs and Complex Human Diseases
Li, J., Xuan, Z., & Liu, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918790 · Cited by 191
“MEG3 was found to be a positive regulator of p53, a tumor suppressor protein [142].”
BackgroundYoung, K. H., Leroy, K., Møller, M. B., Colleoni, G. W. B., Sánchez-Beato, M., Kerbauy, F. R., Haioun, C., Eickhoff, J. C., Young, A. H., Gaulard, P., et al. (2008) · Blood · doi:10.1182/blood-2008-01-129783 · Cited by 191
Structure, Function, and Aggregation of the Zinc-Free Form of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2003) · Biochemistry · doi:10.1021/bi026635n · Cited by 191
Mechanisms of induction of skin cancer by UV radiation
Ananthaswamy, H. N. (1997) · Frontiers in Bioscience · doi:10.2741/a211 · Cited by 189
The biology of breast carcinoma
Keen, J. C., & Davidson, N. E. (2003) · Cancer · doi:10.1002/cncr.11126 · Cited by 189
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
p53 gene mutation: software and database
Beroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 187
A tiger behind many doors: multiple genetic pathways to malignant glioma
Louis, D. N., & Gusella, J. F. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89125-8 · Cited by 185
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
“…more recent nuclear magnetic resonance (NMR) and X-ray studies on tumor-derived core domain mutants have revealed the structural impact of amino-acid residues that are most frequently mutated in human cancers (Cho et al., 1994; Wong et al., 1999; Joerger et al., 2004, 2005a, b; Ang et al., 2006).”
BackgroundCharacterization of the p53-rescue drug CP-31398 in vitro and in living cells
Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., & Fersht, A. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205362 · Cited by 151
“The crystal structure of wild-type core domain complexed with DNA (Cho et al., 1994) provides a structural basis for analysing the e ects of mutation.”
BackgroundCrystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor
Derbyshire, D. J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf383 · Cited by 185
Ryan, K. M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3692 · Cited by 184
“Most of the tumor-derived p53 mutants harbor single amino acid substitutions within the central region which either prevent normal DNA contacting or alter the conformation of this domain (7).”
BackgroundInfluentialQuaternary structures of tumor suppressor p53 and a specific p53 DNA complex
Tidow, H., Melero, R., Mylonas, E., Freund, S. M. V., Grossmann, J. G., Carazo, J. M., Svergun, D. I., Valle, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705069104 · Cited by 170
Liu, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.851 · Cited by 184
Zinc Binding and Redox Control of p53 Structure and Function
Hainaut, P., & Mann, K. (2001) · Antioxidants & Redox Signaling · doi:10.1089/15230860152542961 · Cited by 182
“Several other cysteines are located in the regions that bind within the major groove of target DNA (13).”
InfluentialStructures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181
Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53
Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., & Deb, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6009 · Cited by 182
“Further deletions from the C terminus affecting the DNA-binding domain (4, 12, 34, 81, 115) eliminate the transactivation ability, suggesting that sequence-specific DNA binding is required for wild-type p53-mediated transactivation of the human EGFR promoter.”
BackgroundMolina-Vila, M. A., Bertran-Alamillo, J., Gascó, A., Mayo-de-las-Casas, C., Sánchez-Ronco, M., Pujantell-Pastor, L., Bonanno, L., Favaretto, A. G., Cardona, A. F., Vergnenègre, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2391 · Cited by 181
“In contrast, in advanced, nonresectable NSCLC, where the standard treatment is platinum-based chemotherapy, a proficient DNA repair capacity within the tumor can eliminate the adducts generated by platinum and therefore correlate with a poor prognosis.”
BackgroundInfluentialSolution structure of the single-strand break repair protein XRCC1 N-terminal domain.
Mullen, G. P., Marintchev, A., Mullen, M. A., Maciejewski, M. W., Pan, B., & Gryk, M. R. (1999) · Nature Structural Biology · doi:10.1038/12347 · Cited by 181
Biological and clinical importance of the p53 tumor suppressor gene
Velculescu, V. E., & El-Deiry, W. S. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.6.858 · Cited by 180
Børresen, A., Andersen, T. I., Eyfjörd, J. E., Cornelis, R. S., Thorlacius, S., Borg, Å., Johansson, U., Theillet, C., Scherneck, S., Hartman, S., et al. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140113 · Cited by 178
Metallothionein expression in human neoplasia
Theocharis, S. E., Margeli, A. P., Klijanienko, J. T., & Kouraklis, G. P. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01922.x · Cited by 179
Kouwenhoven, E. N., van Heeringen, S. J., Tena, J. J., Oti, M., Dutilh, B. E., Alonso, M. E., de la Calle-Mustienes, E., Smeenk, L., Rinne, T., Parsaulian, L., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001065 · Cited by 178
“the structure of the DNA-binding domain in p53 that is highly homologous to that in p63, lysine 194 (Q165 in p53) is located in the DNA-binding domain but does not have direct contact with DNA [5,55].”
BackgroundCrystal Structure of a Superstable Mutant of Human p53 Core Domain
Joerger, A. C., Allen, M. D., & Fersht, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309732200 · Cited by 163
Qian, M., Cao, X., Devidas, M., Yang, W., Cheng, C., Dai, Y., Carroll, A., Heerema, N. A., Zhang, H., Moriyama, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5215 · Cited by 176
A role for CH…O interactions in protein-DNA recognition
Mandel-Gutfreund, Y., Margalit, H., Jernigan, R. L., & Zhurkin, V. B. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1660 · Cited by 176
p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels
Kure, E. H., Ryberg, D., Hewer, A., Phillips, D. H., Skaug, V., Bæera, R., & Haugen, A. (1996) · Carcinogenesis · doi:10.1093/carcin/17.10.2201 · Cited by 176
Biochemical properties and biological effects of p53
Haffner, R., & Oren, M. (1995) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(95)90058-6 · Cited by 175
Stengel, A., Schnittger, S., Weissmann, S., Kuznia, S., Kern, W., Kohlmann, A., Haferlach, T., & Haferlach, C. (2014) · Blood · doi:10.1182/blood-2014-02-558833 · Cited by 176
DNA Substrate Dependence of p53-Mediated Regulation of Double-Strand Break Repair
Akyüz, N., Boehden, G. S., Süsse, S., Rimek, A., Preuss, U., Scheidtmann, K.-H., & Wiesmüller, L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6306-6317.2002 · Cited by 175
“For -EGFP/3 EGFP the inhibition was six- and fourfold after wtp53her and p53(1-363)her expression, respectively.”
BackgroundMethodInfluentialStructure of the BRCT Repeats of BRCA1 Bound to a BACH1 Phosphopeptide
Shiozaki, E. N., Gu, L., Yan, N., & Shi, Y. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00238-2 · Cited by 174
Solution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Li, Y., & Prives, C. (2007) · Oncogene · doi:10.1038/sj.onc.1210311 · Cited by 174
“This antibody recognizes a cryptic epitope within the core domain when p53 is unfolded and therefore reflects an altered conformation of the protein (discussed by Cho et al., 1994).”
Background
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.